Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Brian L. Pearlman"'
Autor:
David S. Campo, Ha-Jung Roh, Brian L. Pearlman, Daniel S. Fierer, Sumathi Ramachandran, Gilberto Vaughan, Andrew Hinds, Zoya Dimitrova, Pavel Skums, Yury Khudyakov
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 2, Iss 5, Pp 676-684 (2016)
Background & Aims: The host genetic environment contributes significantly to the outcomes of hepatitis C virus (HCV) infection and therapy response, but little is known about any effects of HCV infection on the host beyond any changes related to adap
Externí odkaz:
https://doaj.org/article/0e6040b618594cb7a3a69c0ac96c2d60
Autor:
Patrick Horne, Anquenette P Sloan, K. Rajender Reddy, Mandana Khalili, Donna M. Evon, Juhi S Moon, Mark S. Sulkowski, Larry Michael, Scott Kixmiller, Michael W. Fried, David R. Nelson, Mitchell L. Shiffman, Meichen Dong, Monika Vainorius, Jama M. Darling, Jodi B Segal, Dawn Fishbein, Joy Peter, Paul W. Stewart, Summer Wadsworth, Kenneth E. Sherman, Brian L. Pearlman, Andrew J. Muir, Giuseppe Morelli, Federico Hinestrosa, Adrian M. Di Bisceglie, Prioritize Study Team, Anna S. Lok
Publikováno v:
Hepatology (Baltimore, Md.). 74(6)
Background and aims Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. Approach and results We conducte
Autor:
Brian L. Pearlman, Bereket T Lodebo
Publikováno v:
Lancet (London, England). 398(10305)
Autor:
Brian L. Pearlman, Andrew Hinds
Publikováno v:
Alimentary Pharmacology & Therapeutics. 48:914-923
Background In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) and glecaprevir/pibrentasvir (G/P) received approval from the U.S. Food and Drug Administration. Although both SOF/VEL/VOX (NS5B polymerase inhib
Autor:
Brian L. Pearlman
Publikováno v:
Clin Liver Dis (Hoboken)
Watch an interview with the author Answer questions and earn CME.
Autor:
Gilberto Vaughan, Daniel S. Fierer, Andrew Hinds, Brian L. Pearlman, David S. Campo, Pavel Skums, Zoya Dimitrova, Ha-Jung Roh, Sumathi Ramachandran, Yury Khudyakov
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 2, Iss 5, Pp 676-684 (2016)
Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology
Background & Aims: The host genetic environment contributes significantly to the outcomes of hepatitis C virus (HCV) infection and therapy response, but little is known about any effects of HCV infection on the host beyond any changes related to adap
Publikováno v:
The American journal of gastroenterology. 114(9)
Objectives Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofos
Autor:
Brian L. Pearlman
Publikováno v:
Annals of Internal Medicine. 171:861
Autor:
Mark S. Sulkowski, Mitchell L. Shiffman, Monika Vainorius, Joy Peter, Ira M. Jacobson, Lois Larsen, Larry Michael, Ira Willner, Anna S. Lok, Wenjing Lu, Gary P. Wang, Michael W. Fried, Giuseppe Morelli, Federico Hinestrosa, K. Rajender Reddy, David R. Nelson, Mohamed Hassan, Jens Kort, Brian L. Pearlman
Publikováno v:
Gastroenterology. 157:1506-1517.e1
Background & Aims Treatment options are limited for patients with hepatitis C (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor. There are some data for the efficacy of glecaprevir/pibrentasvir (G/P) in these patients. We
Autor:
Doreen Fernsler, Bach-Yen Nguyen, Wei Gao, Piero Luigi Almasio, Brynne Tannenbaum, Anjana Grandhi, Eric M. Yoshida, Maria Buti, Beat Muellhaupt, Joan R. Butterton, Rebeca M. Plank, Eliav Barr, Ligita Jancoriene, Brian L. Pearlman, Feng Hsiu Su, J.J. Li, Janice Wahl, Shuyan Wan, John M. Vierling, Hong Liu, Wendy W. Yeh, Aimee Shepherd, Savino Bruno, Hsueh Cheng Huang, Tarek Hassanein, Michael N. Robertson, Frank J. Dutko, Peter Ruane, Eric Lawitz
Background There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials led to the selection of a three-drug regimen of grazoprevir (MK-5172; a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe3ee1d97513e34b0a56aec77c17448
https://www.zora.uzh.ch/id/eprint/146110/
https://www.zora.uzh.ch/id/eprint/146110/